ME00832B - Vezivni proteini uključujući antitjela, derivate antitjela i fragmente antitjela, koji specifično vezuju cd154 i njihova upotreba - Google Patents
Vezivni proteini uključujući antitjela, derivate antitjela i fragmente antitjela, koji specifično vezuju cd154 i njihova upotrebaInfo
- Publication number
- ME00832B ME00832B MEP-2009-281A MEP28109A ME00832B ME 00832 B ME00832 B ME 00832B ME P28109 A MEP28109 A ME P28109A ME 00832 B ME00832 B ME 00832B
- Authority
- ME
- Montenegro
- Prior art keywords
- antibody
- present
- specifically bind
- antibody fragments
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Predmetni pronalazak se odnosi na veziv n e protein e , uključujući a nti t e l a, derivate antitela i fragmente antitela koji specifično vezuju CD154 (CD40L9 protei n .. Predmetni pronalazak takođe obezbeđuje himerna antitela, antitela prilagođena sekvenci čoveka ( humanizovana) i cela humana an t i t e l a , derivate a nti t e l a ili fragmente antit e l a koja se specifično vezuju za e pitop za koji se specifično vezuje humanizovani fragment Fab koji ima varijabilnu sekvencu za težak l anac prema SEQ ID NO l i ima varijabilnu sekvencu za laki lanac prema SEQ ID NO 2. veziv ni protein C D 154 predmetnog pronalaska može da dovede do smanjene efektorske funk c i j e u odnos u na dru go anti-CD 154 an t i t e l o . Vezivni proteini C D 154 predmetnog pronalaska su korisni u dijagnostičkim i terapeutskim metodam a , kao š to je za lečenje i prevenciju bolesti uključujući one koje nose neželjene im unske odgovore ko j i su posred ova ni interakcijama C D 154 - CD4 0 .
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91981607P | 2007-03-22 | 2007-03-22 | |
US91993807P | 2007-03-22 | 2007-03-22 | |
US92049507P | 2007-03-27 | 2007-03-27 | |
PCT/US2008/003735 WO2008118356A2 (en) | 2007-03-22 | 2008-03-21 | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
ME00832B true ME00832B (me) | 2012-03-20 |
Family
ID=39713853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MEP-2009-281A ME00832B (me) | 2007-03-22 | 2008-03-21 | Vezivni proteini uključujući antitjela, derivate antitjela i fragmente antitjela, koji specifično vezuju cd154 i njihova upotreba |
Country Status (36)
Country | Link |
---|---|
US (6) | US8293237B2 (me) |
EP (2) | EP3524626A1 (me) |
JP (3) | JP5721951B2 (me) |
KR (1) | KR101605908B1 (me) |
CN (2) | CN101679521B (me) |
AU (1) | AU2008232409C1 (me) |
BR (2) | BR122020022640B1 (me) |
CA (1) | CA2681530C (me) |
CO (1) | CO6231038A2 (me) |
CR (1) | CR11030A (me) |
CY (1) | CY1121471T1 (me) |
DK (1) | DK2125894T3 (me) |
DO (1) | DOP2009000221A (me) |
EA (1) | EA019636B1 (me) |
EC (1) | ECSP099683A (me) |
ES (1) | ES2713859T3 (me) |
GE (1) | GEP20146112B (me) |
GT (1) | GT200900248A (me) |
HK (2) | HK1139691A1 (me) |
HR (1) | HRP20190312T1 (me) |
HU (1) | HUE041818T2 (me) |
IL (2) | IL201070A (me) |
LT (1) | LT2125894T (me) |
ME (1) | ME00832B (me) |
MX (1) | MX2009010120A (me) |
MY (1) | MY166021A (me) |
NZ (1) | NZ580245A (me) |
PH (1) | PH12013500858A1 (me) |
PL (1) | PL2125894T3 (me) |
PT (1) | PT2125894T (me) |
RS (1) | RS58518B1 (me) |
SG (1) | SG196697A1 (me) |
SI (1) | SI2125894T1 (me) |
TW (1) | TWI417299B (me) |
WO (1) | WO2008118356A2 (me) |
ZA (1) | ZA200907385B (me) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120090094A (ko) * | 2003-06-13 | 2012-08-16 | 바이오겐 아이덱 엠에이 인코포레이티드 | 아글리코실 항-cd154(cd40 리간드) 항체 및 이의 용도 |
EP1791563A4 (en) | 2004-07-26 | 2009-07-08 | Biogen Idec Inc | ANTI-CD154 ANTIBODIES |
TWI417299B (zh) | 2007-03-22 | 2013-12-01 | Biogen Idec Inc | 包括抗體、抗體衍生物及抗體片段之專一性地結合至cd154之結合蛋白及其用途 |
US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
EP2282769A4 (en) * | 2008-04-29 | 2012-04-25 | Abbott Lab | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES |
US9109026B2 (en) * | 2008-06-03 | 2015-08-18 | Abbvie, Inc. | Dual variable domain immunoglobulins and uses thereof |
CA2726087A1 (en) * | 2008-06-03 | 2009-12-10 | Tariq Ghayur | Dual variable domain immunoglobulins and uses thereof |
AU2013203004C1 (en) * | 2008-06-25 | 2022-01-20 | Novartis Ag | Humanization of rabbit antibodies using a universal antibody framework |
CN102164958A (zh) | 2008-06-25 | 2011-08-24 | 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 | 使用通用抗体构架进行的兔抗体的人源化 |
ES2771150T3 (es) * | 2008-06-25 | 2020-07-06 | Novartis Ag | Humanización de anticuerpos de conejo usando un armazón de anticuerpo universal |
KR20110031369A (ko) * | 2008-07-08 | 2011-03-25 | 아보트 러보러터리즈 | 프로스타글란딘 e2 이원 가변 도메인 면역글로불린 및 이의 용도 |
UY32808A (es) * | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
MX2012002651A (es) * | 2009-09-01 | 2012-05-22 | Abbott Lab | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
KR101758942B1 (ko) | 2009-09-24 | 2017-07-17 | 유씨비 파마, 에스.에이. | 박테리아 숙주 균주 |
PE20121531A1 (es) * | 2009-10-15 | 2012-12-22 | Abbott Lab | Inmunoglobulinas con dominio variable dual |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
GB201000591D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
GB201000587D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
GB201000590D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial host strain |
BR112012024713B1 (pt) | 2010-03-31 | 2021-02-17 | Boehringer Ingelheim International Gmbh | anticorpo humanizado, seus usos e composição farmacêutica que o compreende |
GB201012599D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Process for purifying proteins |
CN103298834A (zh) | 2010-08-03 | 2013-09-11 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
CA2809433A1 (en) | 2010-08-26 | 2012-03-01 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
CA2816803A1 (en) * | 2010-11-02 | 2012-05-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
JP6211931B2 (ja) | 2011-03-09 | 2017-10-11 | セル・シグナリング・テクノロジー・インコーポレイテツド | モノクローナル抗体を作製するための方法および試薬 |
CA2852056C (en) | 2011-03-11 | 2021-08-10 | Beth Israel Deaconess Medical Center, Inc. | Anti-cd40 antibodies and uses thereof |
US8852597B2 (en) | 2011-04-04 | 2014-10-07 | The Trustees Of Dartmouth College | Anti-CD154 antibodies having impaired FcR binding and/or complement binding properties |
US9321833B2 (en) | 2011-04-04 | 2016-04-26 | The Trustees Of Dartmouth College | Methods of therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties |
US9028826B2 (en) | 2011-04-04 | 2015-05-12 | The Trustees Of Dartmouth College | Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties |
EP3339325A1 (en) * | 2011-07-13 | 2018-06-27 | UCB Biopharma SPRL | Bacterial host strain expressing recombinant dsbc |
FR2980271B1 (fr) * | 2011-09-16 | 2013-10-11 | Cisbio Bioassays | Procede de determination de la glycosylation d'un anticorps |
SG10201610288TA (en) | 2011-10-13 | 2017-02-27 | Bristol Myers Squibb Co | Antibody polypeptides that antagonize cd40l |
EP2797955A2 (en) | 2011-12-30 | 2014-11-05 | AbbVie Inc. | Dual variable domain immunoglobulins against il-13 and/or il-17 |
GB201208367D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Biological product |
CN104884472B (zh) | 2012-11-01 | 2021-10-15 | 艾伯维公司 | 抗-vegf/dll4双重可变结构域免疫球蛋白及其用途 |
WO2014144280A2 (en) | 2013-03-15 | 2014-09-18 | Abbvie Inc. | DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17 |
US20170269075A1 (en) | 2014-05-12 | 2017-09-21 | Biogen Ma Inc. | Biomarkers predictive of lupus progression and uses thereof |
TWI713453B (zh) | 2014-06-23 | 2020-12-21 | 美商健生生物科技公司 | 干擾素α及ω抗體拮抗劑 |
CA2955984A1 (en) | 2014-07-22 | 2016-01-28 | The University Of Notre Dame Du Lac | Molecular constructs and uses thereof |
CA2960819A1 (en) * | 2014-09-10 | 2016-03-17 | Bristol-Myers Squibb Company | Methods of treating autoimmune disease using a domain antibody directed against cd40l |
CN104288777B (zh) * | 2014-09-18 | 2018-05-29 | 清华大学 | 抗体-高分子结合体、其荧光衍生物及它们的制备方法 |
WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
CA2974511A1 (en) * | 2015-01-22 | 2016-07-28 | Prothena Biosciences Limited | Antibodies recognizing medin |
GB201501613D0 (en) * | 2015-01-30 | 2015-03-18 | Ucb Biopharma Sprl | Treatment of autoimmune disorders with CD154 antibodies |
MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
KR20160132694A (ko) * | 2015-05-11 | 2016-11-21 | 주식회사 프로젠 | Cd154에 특이적으로 결합하는 항체 |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
WO2016208948A1 (ko) * | 2015-06-23 | 2016-12-29 | 서울대학교산학협력단 | Cd154 결합 폴리펩타이드 및 그 용도 |
KR101810778B1 (ko) * | 2015-06-23 | 2017-12-20 | 서울대학교산학협력단 | Cd154 결합 폴리펩타이드 및 그 용도 |
CR20180097A (es) * | 2015-07-14 | 2018-05-25 | Immunext Inc | Anticuerpo anti-cd154 con caracteristicas de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana |
MX2018001522A (es) | 2015-08-05 | 2018-03-15 | Janssen Biotech Inc | Anticuerpos anti-cd154 y metodos de uso de estos. |
CN116063481A (zh) | 2015-09-04 | 2023-05-05 | 普里玛托普医疗股份有限公司 | 人源化抗-cd40抗体及其用途 |
WO2017060242A1 (en) | 2015-10-05 | 2017-04-13 | Ucb Biopharma Sprl | Molecular signatures for use in diagnosis and response to treatment analysis of autoimmune diseases |
RU2018122255A (ru) | 2015-11-27 | 2019-12-19 | Аблинкс Нв | Полипептиды, ингибирующие cd40l |
JP2019509737A (ja) | 2016-03-11 | 2019-04-11 | スカラー ロック インコーポレイテッドScholar Rock,Inc. | TGFβ1結合性免疫グロブリンおよびその使用 |
AU2017370942A1 (en) | 2016-12-07 | 2019-06-13 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
CN117398457A (zh) * | 2017-01-06 | 2024-01-16 | 供石公司 | 亚型特异性、背景许可性TGFβ1抑制剂及其用途 |
WO2018183929A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
CN108929377B (zh) * | 2017-05-23 | 2022-11-11 | 中国科学院上海营养与健康研究所 | Cd40突变体及其在弥漫性大b淋巴瘤的治疗中的应用 |
JP2020521745A (ja) * | 2017-05-24 | 2020-07-27 | エイエルエス・セラピー・デベロップメント・インスティテュートALS Therapy Development Institute | 治療用抗cd40リガンド抗体 |
US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
US20230009902A1 (en) | 2018-06-20 | 2023-01-12 | Progenity, Inc. | Treatment of a disease or condition in a tissue orginating from the endoderm |
KR20210095165A (ko) | 2018-11-19 | 2021-07-30 | 프로제너티, 인크. | 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스 |
CA3145453A1 (en) * | 2019-07-01 | 2021-01-07 | Tonix Pharma Limited | Anti-cd154 antibodies and uses thereof |
US11744875B2 (en) | 2019-07-12 | 2023-09-05 | Op-T Llc | Peptides and methods for treating disease |
CN114269380A (zh) * | 2019-08-23 | 2022-04-01 | Igm生物科学股份有限公司 | IgM糖变体 |
EP4309722A2 (en) | 2019-12-13 | 2024-01-24 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
EP4083211A4 (en) | 2019-12-27 | 2024-07-03 | Chiome Bioscience Inc | ANTI-CDCP1 ANTIBODIES |
KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
CN111518210B (zh) * | 2020-05-11 | 2022-07-19 | 上海米地生物医药有限公司 | 一种特异性识别faim3受体的全人源单抗 |
EP4215211A1 (en) | 2020-09-02 | 2023-07-26 | The University of Tokyo | Tumor immune microenvironment regulator, and preventive, diagnostic or therapeutic use thereof |
WO2023008982A1 (ko) * | 2021-07-30 | 2023-02-02 | 서울대학교산학협력단 | 항 cd154 항체 및 이의 용도 |
CN114149508B (zh) * | 2021-11-25 | 2023-04-28 | 苏州普乐康医药科技有限公司 | 一种结合cd40l的融合蛋白及其应用 |
IL312829A (en) | 2021-12-01 | 2024-07-01 | Biogen Ma Inc | Formulations containing FAB-PEG |
Family Cites Families (143)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
EP0768377A1 (en) | 1988-09-02 | 1997-04-16 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US20040010810A1 (en) | 1990-01-12 | 2004-01-15 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
EP0463151B1 (en) | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
EP0546091B1 (en) | 1990-08-29 | 2007-01-24 | Pharming Intellectual Property BV | Homologous recombination in mammalian cells |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
CA2108147C (en) | 1991-04-10 | 2009-01-06 | Angray Kang | Heterodimeric receptor libraries using phagemids |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
US6136310A (en) | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
US5474771A (en) | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
EP0571613B1 (en) | 1991-12-13 | 2003-09-17 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
CA2135313A1 (en) | 1992-06-18 | 1994-01-06 | Theodore Choi | Methods for producing transgenic non-human animals harboring a yeast artificial chromosome |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US6307026B1 (en) | 1992-12-10 | 2001-10-23 | Celltech Limited | Humanized antibodies directed against A33 antigen |
CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
EP0733070A1 (en) | 1993-12-08 | 1996-09-25 | Genzyme Corporation | Process for generating specific antibodies |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
ES2247204T3 (es) | 1994-01-31 | 2006-03-01 | Trustees Of Boston University | Bancos de anticuerpos policlonales. |
FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
US20050287630A1 (en) | 1995-04-27 | 2005-12-29 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
ATE352613T1 (de) | 1995-08-29 | 2007-02-15 | Kirin Brewery | Chimäres tier und methode zu dessen herstellung |
DE19541844C1 (de) | 1995-11-09 | 1997-07-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
US6013256A (en) | 1996-09-24 | 2000-01-11 | Protein Design Labs, Inc. | Method of preventing acute rejection following solid organ transplantation |
EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
WO1998047531A2 (en) | 1997-04-21 | 1998-10-29 | Arch Development Corporation | Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy |
GB9720054D0 (en) | 1997-09-19 | 1997-11-19 | Celltech Therapeutics Ltd | Biological products |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
ATE419009T1 (de) | 1997-10-31 | 2009-01-15 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
ES2532910T3 (es) | 1998-04-02 | 2015-04-01 | Genentech, Inc. | Variantes de anticuerpos y fragmentos de los mismos |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
ES2230848T3 (es) | 1998-04-28 | 2005-05-01 | Smithkline Beecham Corporation | Anticuerpos monoclonales con inmunogenicidad reducida. |
GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
US6794132B2 (en) | 1999-10-02 | 2004-09-21 | Biosite, Inc. | Human antibodies |
US6680209B1 (en) | 1999-12-06 | 2004-01-20 | Biosite, Incorporated | Human antibodies as diagnostic reagents |
GB0006398D0 (en) * | 2000-03-16 | 2000-05-03 | Novartis Ag | Organic compounds |
US20060257399A1 (en) | 2000-06-28 | 2006-11-16 | Glycofi, Inc. | Immunoglobulins comprising predominantly a Man5GIcNAc2 glycoform |
US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
US7625756B2 (en) | 2000-06-28 | 2009-12-01 | GycoFi, Inc. | Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells |
EP2322644A1 (en) | 2000-06-28 | 2011-05-18 | GlycoFi, Inc. | Methods for producing modified glycoproteins |
AU8867501A (en) * | 2000-09-01 | 2002-03-13 | Biogen Inc | Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
EP1314037A2 (en) | 2000-09-01 | 2003-05-28 | Biogen, Inc. | Methods of designing and producing compounds having improved binding affinity for cd154 or other trimeric proteins |
US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6979556B2 (en) | 2000-12-14 | 2005-12-27 | Genentech, Inc. | Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes |
GB0124317D0 (en) | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
EA007905B1 (ru) | 2001-11-16 | 2007-02-27 | Байоджен Айдек Инк. | Полицистронная экспрессия антител |
GB0129105D0 (en) | 2001-12-05 | 2002-01-23 | Celltech R&D Ltd | Expression control using variable intergenic sequences |
KR101001243B1 (ko) | 2001-12-27 | 2010-12-17 | 글리코파이, 인크. | 포유동물-유형 탄수화물 구조의 설계 방법 |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US20070148171A1 (en) | 2002-09-27 | 2007-06-28 | Xencor, Inc. | Optimized anti-CD30 antibodies |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
ATE328906T1 (de) * | 2002-06-28 | 2006-06-15 | Domantis Ltd | Dual-specifische liganden mit erhöhter halbwertszeit |
US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
ATE528648T1 (de) | 2002-12-03 | 2011-10-15 | Ucb Pharma Sa | Verfahren zum nachweis antikörper-herstellender zellen |
GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
KR20120090094A (ko) | 2003-06-13 | 2012-08-16 | 바이오겐 아이덱 엠에이 인코포레이티드 | 아글리코실 항-cd154(cd40 리간드) 항체 및 이의 용도 |
AU2004220325B2 (en) * | 2003-06-30 | 2011-05-12 | Domantis Limited | Polypeptides |
GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
ES2551439T5 (es) | 2003-07-01 | 2018-11-08 | Ucb Biopharma Sprl | Fragmentos Fab de anticuerpos modificados |
GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
WO2005011376A2 (en) * | 2003-07-26 | 2005-02-10 | Biogen Idec Ma Inc | Altered antibodies having improved antigen-binding affinity |
CA2536408A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
US20060134105A1 (en) | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
GB0329825D0 (en) | 2003-12-23 | 2004-01-28 | Celltech R&D Ltd | Biological products |
EP2053062A1 (en) | 2004-03-24 | 2009-04-29 | Xencor, Inc. | Immunoglobin variants outside the Fc region |
EP1791563A4 (en) * | 2004-07-26 | 2009-07-08 | Biogen Idec Inc | ANTI-CD154 ANTIBODIES |
EP2213683B1 (en) | 2004-08-04 | 2013-06-05 | Mentrik Biotech, LLC | Variant Fc regions |
US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
CN101171263A (zh) | 2005-03-04 | 2008-04-30 | 比奥根艾迪克Ma公司 | 通过合理修饰互补决定区残基使免疫球蛋白可变区人源化的方法 |
CN100369932C (zh) * | 2005-04-07 | 2008-02-20 | 苏州大学 | 抗人cd154单克隆抗体及其应用 |
ES2526811T3 (es) | 2005-08-10 | 2015-01-15 | Macrogenics, Inc. | Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de uso de estos |
ZA200802246B (en) * | 2005-08-15 | 2009-09-30 | Arana Therapeutics Ltd | Engineered antibodies with new world primate framework regions |
NZ568992A (en) | 2005-11-17 | 2012-01-12 | Biogen Idec Inc | Platelet aggregation assays comprising platelet activiating agents and agents that cross-links the CD40L-binding moiety |
TWI417299B (zh) | 2007-03-22 | 2013-12-01 | Biogen Idec Inc | 包括抗體、抗體衍生物及抗體片段之專一性地結合至cd154之結合蛋白及其用途 |
EP3339325A1 (en) * | 2011-07-13 | 2018-06-27 | UCB Biopharma SPRL | Bacterial host strain expressing recombinant dsbc |
-
2008
- 2008-03-21 TW TW097110244A patent/TWI417299B/zh active
- 2008-03-21 SG SG2012055786A patent/SG196697A1/en unknown
- 2008-03-21 HU HUE08742182A patent/HUE041818T2/hu unknown
- 2008-03-21 RS RS20190252A patent/RS58518B1/sr unknown
- 2008-03-21 WO PCT/US2008/003735 patent/WO2008118356A2/en active Application Filing
- 2008-03-21 CN CN200880009361.5A patent/CN101679521B/zh active Active
- 2008-03-21 CN CN201310100838.3A patent/CN103214577B/zh active Active
- 2008-03-21 ME MEP-2009-281A patent/ME00832B/me unknown
- 2008-03-21 JP JP2009554586A patent/JP5721951B2/ja active Active
- 2008-03-21 MX MX2009010120A patent/MX2009010120A/es active IP Right Grant
- 2008-03-21 AU AU2008232409A patent/AU2008232409C1/en active Active
- 2008-03-21 PL PL08742182T patent/PL2125894T3/pl unknown
- 2008-03-21 MY MYPI20093874A patent/MY166021A/en unknown
- 2008-03-21 US US12/532,517 patent/US8293237B2/en active Active
- 2008-03-21 PT PT08742182T patent/PT2125894T/pt unknown
- 2008-03-21 SI SI200832047T patent/SI2125894T1/sl unknown
- 2008-03-21 LT LTEP08742182.2T patent/LT2125894T/lt unknown
- 2008-03-21 CA CA2681530A patent/CA2681530C/en active Active
- 2008-03-21 DK DK08742182.2T patent/DK2125894T3/en active
- 2008-03-21 GE GEAP200811520A patent/GEP20146112B/en unknown
- 2008-03-21 KR KR1020097022091A patent/KR101605908B1/ko active IP Right Grant
- 2008-03-21 EP EP18207475.7A patent/EP3524626A1/en active Pending
- 2008-03-21 BR BR122020022640-4A patent/BR122020022640B1/pt active IP Right Grant
- 2008-03-21 ES ES08742182T patent/ES2713859T3/es active Active
- 2008-03-21 EP EP08742182.2A patent/EP2125894B1/en active Active
- 2008-03-21 NZ NZ580245A patent/NZ580245A/en unknown
- 2008-03-21 BR BRPI0809042-4A patent/BRPI0809042B1/pt active IP Right Grant
- 2008-03-21 EA EA200970879A patent/EA019636B1/ru not_active IP Right Cessation
-
2009
- 2009-09-16 CR CR11030A patent/CR11030A/es unknown
- 2009-09-18 DO DO2009000221A patent/DOP2009000221A/es unknown
- 2009-09-21 GT GT200900248A patent/GT200900248A/es unknown
- 2009-09-21 IL IL201070A patent/IL201070A/en active IP Right Grant
- 2009-10-08 EC EC2009009683A patent/ECSP099683A/es unknown
- 2009-10-14 CO CO09113723A patent/CO6231038A2/es active IP Right Grant
- 2009-10-21 ZA ZA2009/07385A patent/ZA200907385B/en unknown
-
2010
- 2010-05-28 HK HK10105231.6A patent/HK1139691A1/xx unknown
-
2012
- 2012-05-08 IL IL219653A patent/IL219653A0/en unknown
- 2012-10-22 US US13/656,922 patent/US8784823B2/en active Active
-
2013
- 2013-04-29 PH PH12013500858A patent/PH12013500858A1/en unknown
-
2014
- 2014-01-23 HK HK14100728.3A patent/HK1187630A1/xx unknown
- 2014-06-19 US US14/309,118 patent/US9321840B2/en active Active
- 2014-11-19 JP JP2014234483A patent/JP6053744B2/ja active Active
-
2016
- 2016-03-29 US US15/084,088 patent/US20160200823A1/en not_active Abandoned
- 2016-10-19 JP JP2016205115A patent/JP2017036319A/ja active Pending
-
2019
- 2019-02-14 HR HRP20190312TT patent/HRP20190312T1/hr unknown
- 2019-03-04 CY CY20191100259T patent/CY1121471T1/el unknown
- 2019-04-10 US US16/379,844 patent/US20190233530A1/en not_active Abandoned
-
2022
- 2022-09-07 US US17/930,074 patent/US20230135399A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ME00832B (me) | Vezivni proteini uključujući antitjela, derivate antitjela i fragmente antitjela, koji specifično vezuju cd154 i njihova upotreba | |
HRP20191083T1 (hr) | Molekule antitijela za tim-3 i njihove upotrebe | |
HRP20201517T1 (hr) | Anti-cd3 protutijela, anti-cd123 protutijela i bispecifična protutijela koja se specifično vežu na cd3 i/ili cd123 | |
HRP20201156T1 (hr) | Zajednički laki lanci i postupci primjene | |
HRP20171608T1 (hr) | Protutijela koja vežu albumin i njihovi vezujući fragmenti | |
TW200724548A (en) | Antibodies to myostatin | |
AR084210A1 (es) | PROTEINAS DE UNION AL TNF-a | |
HRP20150934T1 (hr) | Djelovanje na abcb5 u terapiji raka | |
CN107428830A (zh) | 单体fc结构域 | |
MX2009009194A (es) | Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes. | |
AR047372A1 (es) | Anticuerpos contra madcam | |
NZ701444A (en) | Antibodies to matrix metalloproteinase 9 | |
EP2511301A3 (en) | Human antibodies to ERBB2 | |
NZ602780A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
HRP20130659A2 (hr) | Protutijela za inzulinu sliäśan receptor faktora i rasta | |
NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
NO20074554L (no) | Antigen bindende molekyler rettet mot MCSP og som har oker FC reseptor bindende affinitet og effektor funksjon | |
EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
HRP20220918T1 (hr) | Anti-transtiretinska antitijela | |
EA201491599A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
HRP20221538T1 (hr) | Anti-transtiretinska antitijela | |
EA201491575A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
RU2018102606A (ru) | Молекулы, связывающиеся с psl pseudomonas, и пути их применения | |
MX2022005850A (es) | Inmunoglobulinas modificadas para seleccionar depositos de amiloide como objetivo. | |
da Rocha et al. | Development of IgY antibodies against anti-snake toxins endowed with highly lethal neutralizing activity |